中文摘要：

目的探讨内吗啡肽（EMs）对糖基化终末产物（AGEs）培养条件下人脐静脉内皮细胞（HUVEC）合成分泌一氧化氮（NO）、内皮型一氧化氮合酶（eNOS）、内皮素1（ET-1）的影响。方法体外制备AGEs修饰的牛血清白蛋白（AGEs—BSA）；分别用AGEs—BSA、EMs（1×10-5、1×10-6、1×10-7、1×10-8mol／LEM1或EM2）＋AGEs—BSA及EMs（1×10-5mol／LEMl或EM2）＋纳洛酮＋AGEs．BSA共同干预HUVEC，同时以只加BSA的HUVEC作为阴性对照。噻唑蓝（MTT）法检测各组HUVEC存活率；放射免疫法检测各组NO、eNOS水平；酶联免疫吸附实验（ELISA）法测定各组ET-1表达量；实时荧光定量聚合酶链反应（RT—PCR）法检测各组eNOS、ET-1mRNA的表达。采用单因素方差分析及t检验进行数据统计。结果与AGEs—BSA组相比，1×10-5mol／LEM1干预组HUVEC存活率增加，NO分泌量减少[分别为0．89±0．05VS0．67±0．02和（14．8±1．4）VS（23．0±0．7）μmol／L，t值分别为9．86、13．18，均P〈0．05]，ET-1产生及其mRNA表达降低[分别为（0．85±0．01）VS（0．99±0．01）μg/L和10．6±0．7VS25．6±1．6，t值分别为31．36、50．18，均P〈0．05]，eNOS活性及其mRNA表达增加[分别为（2．53±0．20）VS（0．61±0．09）U／ml和0．35±0．00VS0．05±0．00，t值分别为21．50、16．80，均P〈0．05]，EM1其他浓度组和EM2各浓度组上述各指标与AGEs—BSA组比较结果相似，差异亦均有统计学意义（t值为2．24～102．4，均P〈0．05）；纳洛酮组上述指标与AGEs—BSA组差异无统计学意义（t值为0．56—2．05，均P〉0．05），而与各浓度EM1或EM2干预组差异有统计学意义（t值为2．24～64．96，均P〈0．05）。结论EMs可提高AGEs—BSA条件下HUVEC的存活率，降低NO、ET-1浓度，提高eNOS浓度；纳洛酮可阻断EMs的上述作用，提示EMs是通过μ阿片受体发挥作用的。

英文摘要：

Objective To discuss the effects of endomorphins （EMs） on synthesis and secretion of vasoactive substances in human umbilical vein endothelial cells （ HUVECs ） under advanced glycation end products （AGEs） injury conditions. Methods HUVECs were stimulated with bovine serum albumin （BSA）, AGEs-BSA, ACEs-BSA ＋EMs （1 × 10-5, 1 × 10-6, 1 × 10-7, and 1 × 10-8 mol/L）, AGEs-BSA ＋ EMs （ 1 × 10 -5 mol/L） ＋ naloxone, respectively. The HUVEC viability was measured by methylthiazolyte- trazolium （MTT） assay,contents of nitric oxide （NO） and endothelial nitric oxide synthase （eNOS） were detected by c010rimetric analysis, level of endothelin-1 （ET-1） was detected by enzyme linked immunoabsorbent assay （ELISA）, expression of eNOS and ET-1 mRNA was measured by reverse transcription polymerase chain reaction （RT-PCR）. Data were analyzed by one-way ANOVA and t test. Results Compared with the cells incubated with AGEs-BSA, the cell viability was significantly enhanced in 1 × 10 -5 mol/L EM1 group （0. 89 ± 0. 05 vs 0. 67 ± 0. 02, t = 9. 86, P 〈 0. 05 ） , while secretion of NO, secretion and mRNA expression of ET-1 was significantly decreased （ （ 14. 8 ± 1.4 ） μmol/L, （ 0. 85 ± 0.01） μg/L, 10. 6 ± 0. 7 vs （23.0 ± 0. 7 ） μmol/L, （0. 99 ± 0. 01 ） μg/L, 25.6 ± 1.6, respectively; t values were 13.18, 31.36, and 50. 18, all P 〈 0. 05 ）, mRNA expression and secretion of eNOS was significantly enhanced （ 0. 35 ± 0. 00, （ 2. 53 ± 0. 20 ） U/ml vs 0. 05 ± 0. 00, （0. 99 ± 0.01 ） U/ml, respectively; t values were 16. 80 and 21.50,both P 〈0. 05）. Similar results were found in other groups of EMs, and the differences were statically significant between the EMs and AGEs-BSA group （ t = 2. 24 to 102. 40, all P 〈 0. 05 ）. There were no significant differences in above-mentioned indices between the AGEs- BSA ＋ EMs ＋ naloxone and AGEs-BSA group （ t = 0. 56 to 2. 05, all P 〉 0.05 ）, but significant differences were found b